LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors FRONT IMMUNOL
Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients Haematologica
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms bioRxiv
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary Future Oncol
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy TRANSPL CELL THER
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia BLOOD ADV
High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion CANCER GENE THER
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis HEMATOL ONCOL
5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics EUR J HAEMATOL